- Dupilumab, sold
under the
brand name
Dupixent, is a
monoclonal antibody blocking interleukin 4 and
interleukin 13
receptor signalling (IL-4R, IL-13R),...
- (Ranolazine), for
stable angina,
marketed by
Gilead Sciences. –
Dermatology Dupixent (Dupilumab), for eczema,
marketed by Regeneron.
Dynabac (Dirithromycin)...
-
lonafarnib capsule". dailymed.nlm.nih.gov.
Retrieved 2021-07-01. "DailyMed -
DUPIXENT-
dupilumab injection, solution". dailymed.nlm.nih.gov.
Retrieved 2021-07-01...
- ISSN 2352-4642. PMID 36370744. S2CID 253470127. "FDA
approves new
eczema drug
Dupixent". U.S. Food and Drug
Administration (FDA). 10
September 2019. Archived...
- the FDA in July 2015, It is
reported to cost $4,500 to $8,000 per year.
Dupixent (dupilumab injection) is for the
treatment of
adolescent and
adult patients'...
-
eczema drug
Dupixent". US Food & Drug Administration. 28
March 2017.
Archived from the
original on 28
March 2017.
Retrieved 29
March 2017. "
Dupixent". European...
- do****ented in
literature include tacrolimus, pimecrolimus, and
dupilumab (
Dupixent). Some
physicians have also seen
positive outcomes with oral doxycycline...
- 1016/S1470-2045(15)00132-1. PMID 26179200. https://www.regeneron.com/sites/default/files/
Dupixent_FPI.pdf [bare URL PDF] http://www.pieris.com/pipeline/respiratory-anem...
- by the
brand name Imuran, has been
reported to be effective.
Dupilumab (
Dupixent) was
approved for
medical use in the
United States in
September 2022. Dupilumab...
- symptoms. In May 2022, U.S. Food and Drug
Administration approved dupilumab (
Dupixent) to
treat eosinophilic esophagitis (EoE) in
adults and
pediatric patients...
